Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Orexo
Deal Size : Inapplicable
Deal Type : Inapplicable
Orexo Announces Positive Data for Powder-based Intranasal Vaccine
Details : Abera's influenza vaccine candidate is administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Orexo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Recipient : Orexo
Deal Size : Undisclosed
Deal Type : Collaboration
Orexo and Abera Collaborate On Nasal Powder Vaccines Using AmorphOX Technology
Details : The collaboration seeks to develop nasal powder vaccines for influenza using Abera's innovative and patented vaccine platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Recipient : Orexo
Deal Size : Undisclosed
Deal Type : Collaboration